Citadel Advisors
XRTX

Citadel Advisors’s XORTX Therapeutics XRTX Stock Holding History

Citadel Advisors’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.5K Buy
+23,116
New +$55.2K ﹤0.01% 13091
2025
Q4 		– Sell
-17,265
Closed -$69.9K – 14279
2025
Q3 		$69.9K Buy
17,265
+9,571
+124% +$40.1K ﹤0.01% 12037
2025
Q2 		$35.8K Buy
+7,694
New +$36.3K ﹤0.01% 11920
2024
Q3 		– Sell
-2,467
Closed -$23.3K – 15393
2024
Q2 		$23.3K Buy
+2,467
New +$33K ﹤0.01% 12502
2023
Q3 		– Sell
-69
Closed -$18.3K – 15242
2023
Q2 		$18.3K Buy
+69
New +$19K ﹤0.01% 12811
2023
Q1 		– Sell
-44
Closed -$14.7K – 15617
2022
Q4 		$14.7K Buy
+44
New +$15.6K ﹤0.01% 13375

Other funds holding XRTX

SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Citadel Advisors's XRTX Position: Q2 2026 in Review

Citadel Advisors opened a new position in XORTX Therapeutics (XRTX) in Q2 2026: 23,116 shares worth $52.5K. The stake represents ﹤0.01% of the portfolio and ranks #13091 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in XRTX as recently as Q3 2025.

Citadel Advisors first reported a position in XRTX in Q4 2022 and has held it in 6 quarters since. The position peaked at $69.9K in Q3 2025. 6 funds tracked by Wall St. Rank hold XRTX as of Q2 2026.

  • Citadel Advisors held 23,116 shares of XORTX Therapeutics worth $52.5K as of Q2 2026.
  • XORTX Therapeutics was a new Citadel Advisors position in Q2 2026.
  • XORTX Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13091 holding.
  • Citadel Advisors first reported a position in XORTX Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • Citadel Advisors's XORTX Therapeutics position peaked at $69.9K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.